QDEL QuidelOrtho Corporation
USHealthcareAs of 2026-07-10 16:00
Why QDEL matters now
QuidelOrtho Corporation (QDEL) is a US stock in Healthcare. The latest InvestLog snapshot shows $18.27 with +4.76% on the session and $1.25B in market capitalization; recent performance reads 1-month +20.12% and YTD -52.14%.
The latest financial table shown here is Q1 2026, with revenue of $619.8M, net income of $-91.8M, and EPS of $-1.35. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -8.1%.
The latest indexable market news headline is "QuidelOrtho: Too Much Uncertainty Around Earnings Keeping Short-Interest Elevated" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Hold with a median target of $12.25; recent insider activity includes Michael Edward L. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.50
P/S
0.35
EV/EBITDA
-6.68
DCF Value
$-45.17
FCF Yield
-8.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
45.0%
Operating Margin
-36.9%
Net Margin
-45.6%
ROE
-56.3%
ROA
-21.5%
ROIC
-19.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $619.8M | $-91.8M | $-1.35 |
| Q4 2025 | $723.6M | $-130.7M | $-1.95 |
| FY 2025 | $2.73B | $-1.13B | $-16.69 |
| Q3 2025 | $699.9M | $-733.0M | $-10.78 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$12.25
Target (Median)
$12.25
Target Range
$12.00 - $12.50
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
0.76
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.